EYEN
vs
S&P 500
EYEN
S&P 500
Over the past 12 months, EYEN has significantly outperformed S&P 500, delivering a return of +112% compared to the S&P 500's +14% growth.
Stocks Performance
EYEN vs S&P 500
Performance Gap
EYEN vs S&P 500
Performance By Year
EYEN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Eyenovia Inc
Glance View
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2018-01-25. The firm is developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of therapeutic indications for pediatric patients with progressive myopia in the United States and patients with age-related near vision impairment, or presbyopia indications. The firm is also developing the microdose fixed combination ophthalmic pharmaceutical for mydriasis. The firm's product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation).
